The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One of the systems that have gained attention in recent times is the gut–brain axis. Although numerous peptides participate in this axis, glucagon-like peptide-1 (GLP-1) plays a central role. GLP-1 is a crucial anorexigenic peptide, with potent abilities to reduce food intake and body weight. The physiological complexity of GLP-1 entails glucose homeostasis, gastrointestinal motility, and the release of insulin and glucagon. As reviewed in this study, acute or repeated treatment with GLP-1 receptor (GLP-1R) agonists decreases alcohol consumption in rodents. Moreover, the abilities of alcohol to promote hyperlocomotion, dopamine release in the nucleus accumbens, and reward in the conditioned place preference paradigm are all suppressed by GLP-1R ligands. Moreover, activation of GLP-1R suppresses the motivation to consume alcohol, alcohol-seeking behaviors, and relapse drinking in male rodents. Similarly, abstinence symptoms experienced during alcohol withdrawal are attenuated by activation of the GLP-1 pathway. On a similar note, the activation of GLP-1 receptors within areas of the brain that are processing reward modulates these alcohol-related responses. Another area that is crucial for this ability is the nucleus of the solitary tract, which is where GLP-1 is produced and from which GLP-1-containing neurons project to areas of reward. These findings may have clinical relevance as AUD is associated with polymorphisms in GLP-1-related genes. Although a GLP-1R agonist does not alter alcohol intake in AUD patients, it reduces this consumption in a sub-population of obese AUD individuals. Given the uncertainty of this outcome, additional clinical studies of obese AUD patients should explore the effects of the GLP-1R agonists on alcohol intake and body weight. Furthermore, GLP-1 receptors modulate the behavioral and neurochemical responses to addictive drugs. Taken together, these preclinical and clinical findings imply that the GLP-1 pathway plays a role in the complex mechanisms regulating alcohol and drug consumption patterns, unveiling a novel aspect of addiction medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal models support that GLP-1RA treatment causally reduces alcohol intake, and GLP-1RAs may dampen the release of dopamine in the nucleus accumbens in response to alcohol intake as well as increase the breakdown of dopamine [17,84,85,86].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 7×
“Moreover, GLP-1 production has been shown in some neurons of the nucleus of the solitary tract (NTS) in the brain stem [for a review, see Holst (2007)].”
BackgroundInfluentialA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“These incretin functions have led to the approval of GLP-1R agonists for the treatment of type II diabetes (Kreymann et al., 1987).”
BackgroundAlcohol, liver disease and the gut microbiota
Bajaj, J. S. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0099-1 · Cited by 697 · cited 1×
“Indeed, alcohol and GLP-1R agonists modify the gut microbiota composition [for reviews, see Bajaj (2019); Sayehmiri et al. (2022)].”
BackgroundREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 3×
“Later on, in the addiction cycle, relapse drinking after alcohol withdrawal is an important aspect of AUD, and this can be modeled using the alcohol deprivation test in rats (Sanchis-Segura and Spanagel, 2006).”
BackgroundCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundAlhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 2×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundRinaman, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.059 · Cited by 311 · cited 1×
“One circuit of interest is the GLP-1-producing neurons from the NTS that target the LDTg, VTA, and NAc (Figure 2) (Rinaman, 2010).”
BackgroundKanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · cited 3×
“Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baas…”
BackgroundKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 2×
“In this study, exenatide does not alter alcohol intake in AUD patients who were of regular weight (Klausen et al., 2022).”
BackgroundFuture Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon
Srivastava, G., & Apovian, C. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0300-4 · Cited by 232
Neurocircuitry of alcohol addiction
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-62619-6.00003-3 · Cited by 225 · cited 2×
“The initial phase is, to a large extent, driven by reward (Koob, 2014), which is regulated by the GLP-1 pathway.”
BackgroundNeurochemical and behavioral studies on ethanol and nicotine interactions
Larsson, A., & Engel, J. A. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.11.010 · Cited by 220
Hayes, M. R., Skibicka, K. P., & Grill, H. J. (2008) · Endocrinology · doi:10.1210/en.2007-1743 · Cited by 214 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207
Self-citationGLP-1 acts on habenular avoidance circuits to control nicotine intake
Tuesta, L. M., Chen, Z., Duncan, A., Fowler, C. D., Ishikawa, M., Lee, B. R., Liu, X.-A., Lu, Q., Cameron, M., Hayes, M. R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4540 · Cited by 200 · cited 4×
“In addition to GLP-1R, the peptide itself appears to be important for this interaction, as the increased levels of GLP-1 after DPP-IV inhibition (with sitagliptin) reduce nicotine consumption in male mice (Tuesta et al., 2017).”
BackgroundInfluentialGut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and Reward
Shirazi, R. H., Dickson, S. L., & Skibicka, K. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061965 · Cited by 187 · cited 6×
“In contrast, Ex4 infusion into the posterior part of the VTA reduces alcohol drinking (Shirazi et al., 2013; Colvin et al., 2020) and decreases alcohol self-administration, without affecting the extinction-induced reacquisition of alcohol self-administration or the motivation to consume alcohol (Dixon et al.”
BackgroundMethodInfluentialAnorexia of infection: current prospects
Langhans, W. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00421-4 · Cited by 183 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundWang, X.-F., Liu, J.-J., Xia, J., Liu, J., Mirabella, V., & Pang, Z. P. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.062 · Cited by 181 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundEgecioglu, E., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069010 · Cited by 175
Self-citationMietlicki-Baase, E. G., Ortinski, P. I., Rupprecht, L. E., Olivos, D. R., Alhadeff, A. L., Pierce, R. C., & Hayes, M. R. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00413.2013 · Cited by 174 · cited 2×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundEgecioglu, E., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077284 · Cited by 158
Self-citationVallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150 · cited 9×
“Similar to the results obtained with acute injection, repeated liraglutide treatment (six injections over 2 weeks) of alcoholexperienced male rats has been shown to decrease both alcohol consumption and preference for alcohol (Vallof et al., 2015).”
BackgroundResultSelf-citationSchmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148 · cited 3×
“, 2016), whereas pharmacological activation amplifies it (Schmidt et al., 2016; Hernandez et al., 2018).”
BackgroundSuchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146 · cited 5×
“The preclinical findings that there is no tolerance development toward the GLP-1R agonists tested and that the decline in drinking persists after treatment discontinuation suggest clinical applicability (Suchankova et al., 2015; Vallof et al., 2015; Vallof et al., 2020).”
BackgroundSelf-citationSørensen, G., Reddy, I. A., Weikop, P., Graham, D. L., Stanwood, G. D., Wortwein, G., Galli, A., & Fink-Jensen, A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.013 · Cited by 140 · cited 5×
“Thus, in male rats, intravenous cocaine self-administration (Sorensen et al., 2015; Fortin and Roitman, 2017; Hernandez et al., 2019) and the reinstatement of cocaine-seeking (Hernandez et al.”
BackgroundInfluentialRubio‐Araiz, A., Porcu, F., Pérez‐Hernández, M., García‐Gutiérrez, M. S., Aracil‐Fernández, M. A., Gutierrez‐López, M. D., Guerri, C., Manzanares, J., O'Shea, E., & Colado, M. I. (2017) · Addiction Biology · doi:10.1111/adb.12376 · Cited by 124 · cited 1×
“It should also be taken into consideration that the treatment outcome after the GLP-1R agonists may be different for rats drinking alcohol or not, as alcohol consumption enhances traversing of the blood–brain barrier (Rubio-Araiz et al., 2017).”
BackgroundHernandez, N. S., Ige, K. Y., Mietlicki-Baase, E. G., Molina-Castro, G. C., Turner, C. A., Hayes, M. R., & Schmidt, H. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0010-3 · Cited by 123 · cited 3×
“, 2016), whereas pharmacological activation amplifies it (Schmidt et al., 2016; Hernandez et al., 2018).”
BackgroundGLP-1 analog attenuates cocaine reward
Graham, D. L., Erreger, K., Galli, A., & Stanwood, G. D. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.141 · Cited by 114
Marty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102 · cited 6×
“In particular, the alcohol intake is unaffected after treatment with either an agonist directed toward protein receptor 119 in the L cells that synthesize GLP-1 or the injection of a DPP-IV inhibitor (Marty et al., 2020).”
BackgroundInfluentialThomsen, M., Dencker, D., Wörtwein, G., Weikop, P., Egecioglu, E., Jerlhag, E., Fink‐Jensen, A., & Molander, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.014 · Cited by 100 · cited 2×
“Indeed, it has been demonstrated that in group-housed male mice, Ex4 increases the latency to the first alcohol bout and decreases the number of alcohol drinks consumed (Thomsen et al., 2017).”
BackgroundSelf-citationHarasta, A. E., Power, J., von Jonquières, G., Karl, T., Drucker, D. J., Housley, G. D., Schneider, M., & Klugmann, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.47 · Cited by 97 · cited 3×
“…with this notion, pharmacologic or genetic suppression of GLP-1R in the lateral septum attenuates the ability of cocaine to activate the mesolimbic dopamine system, as assessed by hyperactivity, reward in the CPP test, and dopamine enhancement in the NAc (Harasta et al., 2015; Reddy et al., 2016).”
BackgroundReddy, I. A., Pino, J. A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R. J., Erreger, K., Wortwein, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.86 · Cited by 96 · cited 2×
“These effects are tentatively mediated via arachidonic acid and the increased expression of the dopamine transporter within the lateral septum (Reddy et al., 2016).”
BackgroundExendin-4 decreases amphetamine-induced locomotor activity
Erreger, K., Davis, A. R., Poe, A. M., Greig, N. H., Stanwood, G. D., & Galli, A. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.03.014 · Cited by 95 · cited 1×
“The hyperactivity (Erreger et al., 2012; Egecioglu et al., 2013c), reward in the CPP test, and dopamine release in the NAc (Egecioglu et al.”
Salinas, C. B. G., Lu, T. T.-H., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A. J., Cornea, A., Conradsen, K., Hecksher-Sørensen, J., Dahl, A. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28496-6 · Cited by 95 · cited 2×
“The processes of passage through the blood–brain barrier and penetration into deeper brain regions differ between the GLP-1R agonists (Salinas et al., 2018).”
BackgroundEffects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Thomsen, M., Holst, J. J., Molander, A., Linnet, K., Ptito, M., & Fink-Jensen, A. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5089-z · Cited by 93 · cited 2×
“Although it has not been compared in any other studies, the efficacy with which liraglutide lowers alcohol consumption is greater than the corresponding efficacy of Ex4 in non-human primates (Thomsen et al., 2019), indicating differences between these GLP-1R agonists.”
BackgroundResultZhang, Y., Kahng, M. W., Elkind, J. A., Weir, V. R., Hernandez, N. S., Stein, L. M., & Schmidt, H. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0531-4 · Cited by 92 · cited 3×
“Similarly, Ex4 reduces oxycodone selfadministration and oxycodone-seeking (Zhang et al., 2020).”
BackgroundInfluentialFortin, S. M., & Roitman, M. F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.019 · Cited by 90 · cited 4×
“, 2015) and phasic dopamine release in the NAc core (Fortin and Roitman, 2017).”
BackgroundInfluentialA novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 88 · cited 2×
“In particular, they target areas that are important for homeostatic feeding, such as the hypothalamus, and for hedonic responses, such as the nucleus accumbens (NAc), ventral tegmental area (VTA), and laterodorsal tegmental area (LDTg) (Alhadeff et al., 2012; Graham et al., 2020).”
BackgroundVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.02.006 · Cited by 84
Self-citationGastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats
Davis, J. F., Schurdak, J. D., Magrisso, I. J., Mul, J. D., Grayson, B. E., Pfluger, P. T., Tschöp, M. H., Seeley, R. J., & Benoit, S. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.035 · Cited by 81
Hernandez, N. S., O'Donovan, B., Ortinski, P. I., & Schmidt, H. D. (2019) · Addiction Biology · doi:10.1111/adb.12583 · Cited by 79 · cited 5×
“Thus, in male rats, intravenous cocaine self-administration (Sorensen et al., 2015; Fortin and Roitman, 2017; Hernandez et al., 2019) and the reinstatement of cocaine-seeking (Hernandez et al.”
BackgroundInfluentialKetogenic diet reduces alcohol withdrawal symptoms in humans and alcohol intake in rodents
Wiers, C. E., Vendruscolo, L. F., van der Veen, J.-W., Manza, P., Kojori, E. S., Kroll, D. S., Feldman, D. E., McPherson, K. L., Biesecker, C. L., Zhang, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6780 · Cited by 77 · cited 2×
“, 2021) and that a ketogenic diet reduces alcohol intake in male rats (Wiers et al., 2021).”
BackgroundResultSirohi, S., Schurdak, J. D., Seeley, R. J., Benoit, S. C., & Davis, J. F. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.04.013 · Cited by 76
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72 · cited 2×
“Ex4 does not alter the ability of morphine to cause hyperactivity, CPP, and withdrawal symptoms or remifentanil intake in male rodents (Bornebusch et al., 2019).”
BackgroundVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 72 · cited 9×
“These dulaglutide-mediated reductions in alcohol drinking and preference for alcohol were also evident in female rats (Vallof et al., 2020), an outcome that was not seen previously.”
BackgroundResultSelf-citationEffects of the GLP‐1 Agonist Exendin‐4 on Intravenous Ethanol Self‐Administration in Mice
Sørensen, G., Caine, S. B., & Thomsen, M. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13199 · Cited by 69 · cited 1×
“However, this is unlikely, as Ex4 reduces intravenous self-administration of alcohol in male mice (Sorensen et al., 2016) and the GLP-1R agonist does not reduce water intake.”
BackgroundHernandez, N. S., Weir, V. R., Ragnini, K., Merkel, R., Zhang, Y., Mace, K., Rich, M. T., Christopher Pierce, R., & Schmidt, H. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00957-3 · Cited by 67 · cited 1×
“When considering LDTg, Ex4 infusion into this area suppresses cocaine-related behaviors (Hernandez et al., 2020).”
BackgroundAmylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior
Mietlicki-Baase, E. G., McGrath, L. E., Koch-Laskowski, K., Krawczyk, J., Reiner, D. J., Pham, T., Nguyen, C. T. N., Turner, C. A., Olivos, D. R., Wimmer, M. E., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.024 · Cited by 66 · cited 2×
“Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baas…”
BackgroundColvin, K. J., Killen, H. S., Kanter, M. J., Halperin, M. C., Engel, L., & Currie, P. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249710 · Cited by 61 · cited 3×
“Other GLP-1R-containing brain areas that participate in this suppression of alcohol-linked behaviors are the lateral hypothalamus and dorsomedial hippocampus (Colvin et al., 2020).”
BackgroundVallöf, D., Vestlund, J., & Jerlhag, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.020 · Cited by 61
Self-citationDouton, J. E., Augusto, C., Stoltzfus, B., Carkaci-Salli, N., Vrana, K. E., & Grigson, P. S. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000609 · Cited by 60 · cited 1×
“When considering heroin, Ex4 attenuates withdrawal symptoms during heroin abstinence and diminishes heroin-seeking in male rats (Douton et al., 2021).”
BackgroundEdvardsson, C. E., Vestlund, J., & Jerlhag, E. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174039 · Cited by 57 · cited 1×
“release in the VTA, an effect that modulates the ability of alcohol to activate the mesolimbic dopamine system (Edvardsson et al., 2021).”
BackgroundSelf-citationSharma, A. N., Pise, A., Sharma, J. N., & Shukla, P. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9627-z · Cited by 54
Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats
Abtahi, S., Howell, E., & Currie, P. J. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001071 · Cited by 51 · cited 1×
“Likewise, this treatment reduces alcohol drinking in both male and female rats (Abtahi et al., 2018; Vallof et al., 2019a; Colvin et al., 2020).”
BackgroundBouhlal, S., Ellefsen, K. N., Sheskier, M. B., Singley, E., Pirard, S., Gorelick, D. A., Huestis, M. A., & Leggio, L. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.07.033 · Cited by 51 · cited 2×
“, 2019) and reduces the corresponding levels in humans (Bouhlal et al., 2017).”
BackgroundAn Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side
Shevchouk, O. T., Tufvesson‐Alm, M., & Jerlhag, E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.774050 · Cited by 47 · cited 2×
“…and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baase et al., 2013; Baisley and Baldo, 2014; Mietlicki-Baase et al., 2017; Rodriguez et al., 2018), 3) they enhance water intake, and 4) they reduce alcohol/drug responses that are unaffected by aversion [for a review, see Shevchouk et al. (2021)].”
BackgroundSelf-citationRebosio, C., Balbi, M., Passalacqua, M., Ricciarelli, R., & Fedele, E. (2018) · BioFactors · doi:10.1002/biof.1406 · Cited by 46 · cited 3×
“To date, GLP-1R has been identified presynaptically on GABAergic nerve terminals (Rebosio et al., 2018) and on medium spiny neurons that express the dopamine-D1 or dopamine-D2 receptors (Zhang et al., 2020).”
BackgroundInfluentialFarokhnia, M., Browning, B. D., Crozier, M. E., Sun, H., Akhlaghi, F., & Leggio, L. (2022) · Addiction Biology · doi:10.1111/adb.13211 · Cited by 46 · cited 3×
“One human study has contributed to this identification as it shows that the hippocampal expression of GLP-1R is higher in patients with AUD than in controls (Farokhnia et al., 2022).”
BackgroundInfluentialAmylin Receptor Signaling in the Nucleus Accumbens Negatively Modulates μ-opioid-Driven Feeding
Baisley, S. K., & Baldo, B. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.153 · Cited by 38 · cited 1×
“Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baas…”
BackgroundContemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 38 · cited 1×
“This rapid degradation of GLP-1 has motivated the development of long-acting GLP-1R agonists, which are protected from DPP-IV degradation and can be used clinically (Kalra et al., 2021).”
BackgroundDixon, T. N., McNally, G. P., & Ong, Z. Y. (2020) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14437 · Cited by 37 · cited 1×
“, 2020) and decreases alcohol self-administration, without affecting the extinction-induced reacquisition of alcohol self-administration or the motivation to consume alcohol (Dixon et al., 2020).”
BackgroundGLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Holst, J. J., & Seino, Y. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.017 · Cited by 33 · cited 1×
“One of the best-known activities of GLP-1 is the normalization of plasma glucose levels, achieved through the facilitation of insulin secretion and lowering of glucagon secretion (Holst and Seino, 2009).”
BackgroundYou, Z.-B., Wang, B., Gardner, E. L., & Wise, R. A. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.001 · Cited by 31 · cited 1×
“In contrast to alcohol, cocaine intake increases the GLP-1 levels in the plasma in rodents (You et al., 2019) and reduces the corresponding levels in humans (Bouhlal et al.”
BackgroundWallenius, V., Elias, E., Elebring, E., Haisma, B., Casselbrant, A., Larraufie, P., Spak, E., Reimann, F. M., le Roux, C. W., Docherty, N. G., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319372 · Cited by 31 · cited 1×
“For instance, ketogenic diets or ketone supplements alter the production of GLP-1 (Wallenius et al., 2020).”
BackgroundGlucagon-like peptide-1 receptors and sexual behaviors in male mice
Vestlund, J., & Jerlhag, E. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104687 · Cited by 31
Self-citationDopamine and Alcohol Dependence: From Bench to Clinic
Jayaram-Lindström, N., Ericson, M., Steensland, P., & Jerlhag, E. (2016) · Recent Advances in Drug Addiction Research and Clinical Applications · doi:10.5772/63144 · Cited by 29
Self-citationSharma, A. N., Pise, A., Sharma, J. N., & Shukla, P. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9603-7 · Cited by 29
Vestlund, J., & Jerlhag, E. (2020) · Hormones and Behavior · doi:10.1016/j.yhbeh.2020.104778 · Cited by 28
Self-citationDPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice
Lautar, S. L., Rojas, C. J., Slusher, B. S., Wozniak, K. M., Wu, Y., Thomas, A. G., Waldon, D. J., Li, W., Ferraris, D. V., & Belyakov, S. A. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.069 · Cited by 25 · cited 1×
“Although an increased circulating level of GLP-1 does not modulate alcohol-related responses, it mediates the behavioral responses to amphetamine (Lautar et al., 2005).”
BackgroundŁupina, M., Talarek, S., Kotlinska, J. H., Gibuła‐Tarłowska, E., Listos, P., & Listos, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104616 · Cited by 22 · cited 13×
“The hyperactivity (Erreger et al., 2012; Egecioglu et al., 2013c), reward in the CPP test, and dopamine release in the NAc (Egecioglu et al., 2013c) observed after amphetamine intake are reduced by acute systemic administration of Ex4 to male mice.”
BackgroundInfluentialCagniard, B., & Murphy, N. P. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.08.021 · Cited by 18
Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study
Tsermpini, E. E., Goričar, K., Plesničar, B. K., Ilješ, A. P., & Dolžan, V. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.908948 · Cited by 18 · cited 1×
“However, this association was not found in another human genetic study (Tsermpini et al., 2022).”
BackgroundGerner, T., Johansen, O.-E., Olufsen, M., Torjesen, P. A., & Tveit, A. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2013.877594 · Cited by 16 · cited 1×
“However, the efficacy of GLP-1R agonists to reduce drinking in this subgroup may diverge from those without surgery, as GLP-1 is increased after surgery (Gerner et al., 2014).”
BackgroundRodriguez, J. A., Fehrentz, J., Martínez, J., Salah, K. B. H., & Wellman, P. J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.10.017 · Cited by 15 · cited 1×
“Although indirectly excluding this factor, the tested GLP-1R agonists act as follows: 1) they do not cause a CPP per se as an indication of conditioned aversion (Cagniard and Murphy, 2012), 2) they are used in dosages that are not associated with malaise (Cagniard and Murphy, 2012; Kanoski et al., 2012; Mietlicki-Baas…”
BackgroundGut peptide hormones: Importance for food intake
Näslund, E. B., Schmidt, P. T., & Hellström, P. M. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410010634 · Cited by 13 · cited 1×
“Indeed, activation of GLP-1R reduces both homeostatic and hedonic feeding, and it decreases appetite (Tang-Christensen et al., 1996; Turton et al., 1996; Langhans, 2000; Naslund et al., 2005; Hayes et al., 2008; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013; Wang et al., 2015).”
BackgroundSuppression of an ethanol withdrawal syndrome in rats by butyrate, lactate and β-hydroxybutyrate
Derr, R. F., Draves, K., & Derr, M. I. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90237-0 · Cited by 11 · cited 1×
“In support of this idea, initial human and rodent studies have revealed that ketogenic diets reduce the withdrawal symptoms after alcohol exposure (Derr et al., 1983;Wiers et al., 2021) and that a ketogenic diet reduces alcohol intake in male rats (Wiers et al.”
ResultActivation of glucagon‐like peptide‐1 receptors and skilled reach foraging
Vestlund, J., Bergquist, F., Licheri, V., Adermark, L., & Jerlhag, E. (2020) · Addiction Biology · doi:10.1111/adb.12953 · Cited by 8 · cited 1×
“Different treatment outcomes linked to the different GLP-1R agonists should also be evaluated, since dulaglutide (in contrast to Ex4 or liraglutide) augments the learning of skilled reach foraging (Vestlund et al., 2020).”
BackgroundSelf-citationGut Microbiota Modification via Glucagon-like Peptide-1 with Beneficial Neuroprotective Effects
Sayehmiri, F., Samadian, M. M., Mohamadkhani, A., Tafakhori, A., Haghighat, S., Rahmatian, A., Mohammadkhani, M. A., Fazli, H. R., & Rezaei–Tavirani, M. (2022) · Middle East Journal of Digestive Diseases · doi:10.34172/mejdd.2022.278 · Cited by 5 · cited 1×
“Indeed, alcohol and GLP-1R agonists modify the gut microbiota composition [for reviews, see Bajaj (2019); Sayehmiri et al. (2022)].”
BackgroundMerchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
Research works printed but not linked: 1
- Kalra, S. (2011). Change in alcohol consumption following liraglutide initiation: A real life experience. California, USA: 71st Anerican Diabetes Association confernace, 2019.
Cited by
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4789 · Cited by 287
McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2295397 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“One of the important aspects of the anorectic effects of GLP-1RAs is their effect on the reward system 225,226 .”
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
Metadata
- Authors
- Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Jerlhag, Elisabet
- ORCID
- Jerlhag, Elisabet
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-30
- Volume
- 14
- Pages
- 1063033-1063033
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10097922
- OpenAlex
- W4361280631
- Cited by
- 80
- References
- 80
- Citations by year
- 2026: 17 · 2025: 36 · 2024: 20 · 2023: 7
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet
- Hjärnfonden
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, alcoholism, addiction, gut-brain axis, alcohol withdrawal, nucleus tractus solitarius, nucleus accumbens dopamine, conditioned place preference, alcohol relapse, obesity, genetic polymorphism, drug addiction, anorexigenic peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.